Liver transplantation(LT)has made significant progress in the treatment of end stage liver disease(ESLD).However,many patients still die from disease progression while awaiting transplantation.As the number of patient...Liver transplantation(LT)has made significant progress in the treatment of end stage liver disease(ESLD).However,many patients still die from disease progression while awaiting transplantation.As the number of patients on LT waiting lists is increasing,and the organ shortage crisis is obvious,various efforts have been made to increase the pool of available liver grafts[1].In addition to living donor liver transplantation(LDLT),improving the utilization rate of extended criteria donor(ECD)livers is an important way.However,under traditional cold storage,ECD livers are usually associated with a higher risk of ischemic biliary disease,early allograft dysfunction(EAD)or even primary nonfunction(PNF).The frequently described definition in the literature for ECD grafts generally includes elderly,steatotic,long cold ischemia time(CIT),grafts obtained from donation after circulatory death(DCD),split liver grafts,donors with increased risk of infectious disease transmission and prolonged donor intensive care unit stay[2].展开更多
Liver transplantation remains the most effective treatment for end-stage liver disease(ESLD),but it is fraught with challenges such as immunosuppression,high risk and cost,and donor shortage.In recent years,stem cell ...Liver transplantation remains the most effective treatment for end-stage liver disease(ESLD),but it is fraught with challenges such as immunosuppression,high risk and cost,and donor shortage.In recent years,stem cell transplantation has emerged as a promising new strategy for ESLD treatment,with mesenchymal stem cells(MSCs)gaining significant attention because of their unique properties.MSCs can regulate signaling pathways,including hepatocyte growth factor/c-Met,Wnt/beta(b)-catenin,Notch,transforming growth factor-b1/Smad,interleukin-6/Janus kinase/signal transducer and activator of transcription 3,and phosphatidylinositol 3-kinase/PDK/Akt,thereby influencing the progression of liver fibrosis and regeneration.As a promising stem cell type,MSCs offer numerous advantages in liver disease treatment,including low immunogenicity;ease of acquisition;unlimited proliferative ability;pluripotent differentiation potential;immunomodulatory function;and anti-inflammatory,antifibrotic,and antiapoptotic biological characteristics.This review outlines the mechanisms by which MSCs reverse liver fibrosis and promote liver regeneration.MSCs are crucial in reversing liver fibrosis and repairing liver damage through the secretion of growth factors,regulation of signaling pathways,and modulation of immune responses.MSCs have shown good therapeutic effects in preclinical and clinical studies,providing new strategies for liver disease treatment.However,challenges still exist in the clinical application of MSCs,including low differentiation efficiency and limited sources.This review provides a reference for MSC application in liver disease treatment.With the continuous progress in MSC research,MSCs are expected to achieve breakthroughs in liver disease treatment,thereby improving patient treatment outcomes.展开更多
文摘Liver transplantation(LT)has made significant progress in the treatment of end stage liver disease(ESLD).However,many patients still die from disease progression while awaiting transplantation.As the number of patients on LT waiting lists is increasing,and the organ shortage crisis is obvious,various efforts have been made to increase the pool of available liver grafts[1].In addition to living donor liver transplantation(LDLT),improving the utilization rate of extended criteria donor(ECD)livers is an important way.However,under traditional cold storage,ECD livers are usually associated with a higher risk of ischemic biliary disease,early allograft dysfunction(EAD)or even primary nonfunction(PNF).The frequently described definition in the literature for ECD grafts generally includes elderly,steatotic,long cold ischemia time(CIT),grafts obtained from donation after circulatory death(DCD),split liver grafts,donors with increased risk of infectious disease transmission and prolonged donor intensive care unit stay[2].
文摘Liver transplantation remains the most effective treatment for end-stage liver disease(ESLD),but it is fraught with challenges such as immunosuppression,high risk and cost,and donor shortage.In recent years,stem cell transplantation has emerged as a promising new strategy for ESLD treatment,with mesenchymal stem cells(MSCs)gaining significant attention because of their unique properties.MSCs can regulate signaling pathways,including hepatocyte growth factor/c-Met,Wnt/beta(b)-catenin,Notch,transforming growth factor-b1/Smad,interleukin-6/Janus kinase/signal transducer and activator of transcription 3,and phosphatidylinositol 3-kinase/PDK/Akt,thereby influencing the progression of liver fibrosis and regeneration.As a promising stem cell type,MSCs offer numerous advantages in liver disease treatment,including low immunogenicity;ease of acquisition;unlimited proliferative ability;pluripotent differentiation potential;immunomodulatory function;and anti-inflammatory,antifibrotic,and antiapoptotic biological characteristics.This review outlines the mechanisms by which MSCs reverse liver fibrosis and promote liver regeneration.MSCs are crucial in reversing liver fibrosis and repairing liver damage through the secretion of growth factors,regulation of signaling pathways,and modulation of immune responses.MSCs have shown good therapeutic effects in preclinical and clinical studies,providing new strategies for liver disease treatment.However,challenges still exist in the clinical application of MSCs,including low differentiation efficiency and limited sources.This review provides a reference for MSC application in liver disease treatment.With the continuous progress in MSC research,MSCs are expected to achieve breakthroughs in liver disease treatment,thereby improving patient treatment outcomes.
